Physician profile
Gerald Markovitz
NPI 1992788426
$11,330.57
in general payments reported to CMS, 2019-2025
17 companies · $464 in 2025
The $464 reported for 2025 was more than what 77% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,666 · 2020: $4,178 · 2021: $513 · 2022: $639 · 2023: $397 · 2024: $473 · 2025: $464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,098 · Education: $235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,098.44 |
| Education | $235.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $8,397.46 | 2019-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $1,291.60 | 2019-2025 | Fasenra, Tezspire |
| Regeneron Healthcare Solutions, INC. | $405.27 | 2019-2025 | Dupixent |
| Genzyme Corporation | $278.45 | 2021-2025 | |
| Mylan Specialty L.P. | $151.36 | 2020-2024 | Yupelri |
| Grifols USA, LLC | $142.33 | 2024-2025 | Prolastin-C Liquid |
| Amgen INC. | $105.40 | 2022-2024 | Tezspire |
| Mallinckrodt Hospital Products INC. | $89.07 | 2021-2024 | Acthar |
| Paratek Pharmaceuticals, INC. | $72.11 | 2020-2021 | |
| Philips North America LLC | $71.70 | 2024-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Genentech USA, INC. | $69.47 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $60.49 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $55.16 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.53 | 2021-2022 | |
| Circassia INC. | $38.28 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $25.17 | 2025 | Ohtuvayre |
| Viatris Specialty LLC | $24.72 | 2025 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Markovitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.